YU63702A - Novo antitelo sa specifičnošću za rak debelog creva - Google Patents

Novo antitelo sa specifičnošću za rak debelog creva

Info

Publication number
YU63702A
YU63702A YU63702A YUP63702A YU63702A YU 63702 A YU63702 A YU 63702A YU 63702 A YU63702 A YU 63702A YU P63702 A YUP63702 A YU P63702A YU 63702 A YU63702 A YU 63702A
Authority
YU
Yugoslavia
Prior art keywords
target
specificity
colon cancer
novel antibody
binds
Prior art date
Application number
YU63702A
Other languages
English (en)
Inventor
Thomas N. Brodin
Pia J. Karlstrom
Bo H.K. Nilson
Lennart G. Ohlsson
Jesper M. Tordsson
Original Assignee
Active Biotech Ab.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab. filed Critical Active Biotech Ab.
Publication of YU63702A publication Critical patent/YU63702A/sh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Vezujuća struktura koja se vezuje u, i/ili za površinu ćelija tumora; ciljna struktura koja je izložena i/ili eksprimirana u, ili na površini ćelija tumora; vezujuća struktura koja prepoznaje i blokira pomenutu ciljnu strukturu; substanca koja se vezuje za ili blokira ekspresiju pomenute ciljne strukture; farmaceutska kompozicija koja sadrži pomenutu vezujuću strukturu, ciljne strukture ili substancu kao aktivan princip; kompozicija vakcine koja sadrži pomenute ciljne strukture kao aktivan princip; metod za selekciju faga; i metode za in vitro i in vivo dijagnoze i prognoze, i tretman humanih malignih oboljenja koji sadrži upotrebu gore opisanih tema, kao što je opisano.[A binding structure which binds in, and/or to the surface of, tumour cells; a target structure displayed and/or expressed in, or on the surface of, tumour cells; a binding structure that recognises and blocks said target structure; a substance that binds to or blocks the expression of said target structure; pharmaceutical compositions comprising said binding structure, target structures or substance as active principles; vaccine compositions comprising said target structures as active principles; a method for phage selection; and methods of in vitro and in vivo diagnosis and prognosis, and of treatment of human malignant diseases comprising the use of the above subject matters, are described.
YU63702A 2000-02-24 2001-02-23 Novo antitelo sa specifičnošću za rak debelog creva YU63702A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0000597A SE0000597D0 (sv) 2000-02-24 2000-02-24 Novel antibody

Publications (1)

Publication Number Publication Date
YU63702A true YU63702A (sh) 2006-01-16

Family

ID=20278567

Family Applications (1)

Application Number Title Priority Date Filing Date
YU63702A YU63702A (sh) 2000-02-24 2001-02-23 Novo antitelo sa specifičnošću za rak debelog creva

Country Status (22)

Country Link
US (1) US7425623B2 (sh)
EP (1) EP1257291A1 (sh)
JP (1) JP2003523213A (sh)
KR (1) KR20020079888A (sh)
CN (1) CN1406136A (sh)
AU (1) AU775876B2 (sh)
BR (1) BR0108609A (sh)
CA (1) CA2400661A1 (sh)
EE (1) EE200200473A (sh)
HK (1) HK1052648A1 (sh)
HU (1) HUP0300007A3 (sh)
IL (1) IL151325A0 (sh)
MX (1) MXPA02008315A (sh)
NO (1) NO20023670L (sh)
NZ (1) NZ520523A (sh)
PL (1) PL356386A1 (sh)
RU (1) RU2268068C2 (sh)
SE (1) SE0000597D0 (sh)
SK (1) SK11982002A3 (sh)
WO (1) WO2001062286A1 (sh)
YU (1) YU63702A (sh)
ZA (1) ZA200206039B (sh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003008450A1 (fr) * 2001-06-12 2003-01-30 Kyogo Itoh Antigenes tumoraux
US20030206916A1 (en) 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
CN1303105C (zh) * 2003-12-08 2007-03-07 陈志南 抗人大肠癌单克隆抗体CAb—2轻、重链可变区基因及其应用
TWI429658B (zh) * 2006-06-07 2014-03-11 Bioalliance Cv 辨認癌症細胞上表現的ｃｄ４３與ｃｅａ之含碳水化合物抗原決定區的抗體及其使用方法
EP2048241B1 (en) * 2007-10-08 2012-07-25 Sividon Diagnostics GmbH Method employing GAPDH as molecular markers for cancer prognosis
JP5568478B2 (ja) * 2007-12-18 2014-08-06 バイオアライアンス セー．フェー． 癌細胞で発現するｃｄ−４３およびｃｅａの炭水化物含有エピトープを認識する抗体およびそれを使用する方法
ES2432537T3 (es) * 2008-09-01 2013-12-04 National University Corporation Nagoya University Pronóstico de cánceres de colon
FR2945952B1 (fr) * 2009-05-27 2013-10-04 Univ Claude Bernard Lyon Anticorps anti-ck8 pour utilisation comme medicament.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798257A (en) * 1990-07-09 1998-08-25 Research Corporation Technologies, Inc. Nucleic acid encoding human MTS-1 protein
US5994088A (en) * 1991-03-08 1999-11-30 Board Of Trustees Of The University Of Illinois Methods and reagents for preparing and using immunological agents specific for P-glycoprotein
JP3782100B2 (ja) * 1992-08-07 2006-06-07 エピミューン，インコーポレイティド Ｈｌａ結合性ペプチド及びその用途
US5972643A (en) * 1994-06-17 1999-10-26 Fred Hutchinson Cancer Research Center Isolated polynucleotide molecules encoding CTCF, a CCCTC-binding factor
WO1997002479A2 (en) * 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
US20020193571A1 (en) * 1996-01-08 2002-12-19 Paul J. Carter Wsx receptor agonist antibodies
EP0879183A1 (fr) 1996-07-18 1998-11-25 Montania Bouchon avec recipient auxiliaire et procede de realisation
EP0934526B1 (en) * 1996-10-08 2003-01-08 U-BISys B.V. Methods and means for selecting peptides and proteins having specific affinity for a target
SE9700291D0 (sv) * 1997-01-31 1997-01-31 Pharmacia & Upjohn Ab Selection method and prodcts resulting therefrom
ES2246069T3 (es) * 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
JP2001513995A (ja) * 1997-08-29 2001-09-11 セレクティブ ジェネティックス， インコーポレイテッド 遺伝子送達のためのインターナリゼーションリガンドを選択するためのファージディスプレイを使用する方法
DE19739525A1 (de) * 1997-09-09 1999-09-30 Heinrich Abbrederis Die Vorrichtung T.C.Reinigungskopf ermöglicht die Reinigung, Schmierung und Konservierung von Ketten im eingebauten und ausgebauten Zustand unter minimalen Platzverhältnissen
EP0934953A2 (en) * 1997-12-03 1999-08-11 Boehringer Mannheim Corporation Complex specific antibodies, method of preparation and uses thereof
IL144559A0 (en) * 1999-03-01 2002-05-23 Genentech Inc Antibodies for cancer therapy and diagnosis

Also Published As

Publication number Publication date
SK11982002A3 (sk) 2003-03-04
MXPA02008315A (es) 2002-12-09
HK1052648A1 (zh) 2003-09-26
AU3629401A (en) 2001-09-03
EP1257291A1 (en) 2002-11-20
EE200200473A (et) 2004-02-16
US7425623B2 (en) 2008-09-16
JP2003523213A (ja) 2003-08-05
NO20023670L (no) 2002-08-23
RU2268068C2 (ru) 2006-01-20
CN1406136A (zh) 2003-03-26
PL356386A1 (en) 2004-06-28
US20030176661A1 (en) 2003-09-18
AU775876B2 (en) 2004-08-19
KR20020079888A (ko) 2002-10-19
ZA200206039B (en) 2003-07-29
WO2001062286A1 (en) 2001-08-30
CA2400661A1 (en) 2001-08-30
NO20023670D0 (no) 2002-08-02
NZ520523A (en) 2004-08-27
RU2002125386A (ru) 2004-03-20
IL151325A0 (en) 2003-04-10
BR0108609A (pt) 2002-11-19
HUP0300007A2 (en) 2003-05-28
HUP0300007A3 (en) 2005-11-28
SE0000597D0 (sv) 2000-02-24

Similar Documents

Publication Publication Date Title
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2003042661A8 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
EP1383785A4 (en) RECOMBINANT, TUMOR-SPECIFIC ANTIBODIES AND THEIR USE
MXPA03001634A (es) Polipeptido tumoral cripto.
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
WO2001094641A3 (en) Gene targets and ligands that bind thereto for treatment and diagnosis of ovarian carcinomas
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
WO2002060317A3 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2001072295A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
EP2175879A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH PRION PROTEIN
WO2006027693A8 (en) Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis
WO2002012328A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2004046332A3 (en) Amplified genes involved in cancer
WO2003079982A3 (en) Gene amplification in cancer
WO2005054295A8 (en) Therapeutic and diagnostic anti-hsp 70 antibodies
WO2002058534A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
YU63702A (sh) Novo antitelo sa specifičnošću za rak debelog creva
WO2002053700A3 (en) Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
EA201690004A1 (ru) Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
WO2005065361A3 (en) Compounds and compositions for treating dysproliferative diseases, and methods of use thereof
WO2003044161A3 (en) Gene amplification and overexpression in cancer
WO2001077168A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2002012280A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001090152A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer